08.09.2009 18:19:00

Exact Sciences to Present at Baird, Rodman & Renshaw Conferences

EXACT Sciences Corp. (Nasdaq: EXAS) today announced that it will present at Robert W. Baird & Co.’s 2009 Health Care Conference, which is being held Sept. 9-10, at the Four Seasons Hotel in New York, and the Rodman & Renshaw Annual Global Investment Conference, which is being held Sept. 9-11, at the New York Palace Hotel.

Kevin T. Conroy, Exact’s president and chief executive, will make the company’s presentation at the Baird conference on Thursday, Sept. 10, at 11 a.m. ET. He will make the company’s presentation at the Rodman & Renshaw conference on Thursday, Sept. 10 at 4:05 p.m. ET.

A live webcast of the Baird presentation will be available through the company’s web site at www.exactsciences.com and at www.wsw.com/webcast/baird9/exas/. A live webcast of the Rodman & Renshaw presentation also will be available through the company’s web site and at www.wsw.com/webcast/rrshq15/exas. An archive of the webcasts will be available following the conclusion of the conferences.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Certain statements made in this press contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe,” "expect,” "may,” "will,” "should,” "could,” "seek,” "intend,” "plan,” "estimate,” "anticipate” or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports of Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu EXACT Sciences Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

EXACT Sciences Corp. 51,77 -0,31% EXACT Sciences Corp.

Indizes in diesem Artikel

NASDAQ Comp. 19 954,30 -0,50%